Latest News by Industry
DURHAM, N.C. (AP) — DURHAM, N.C. (AP) — BioCryst Pharmaceuticals Inc. (BCRX) on Tuesday reported a loss of $71.5 million in its fourth quarter.
On a per-share basis, the Durham, North Carolina-based company said it had a loss of 38 cents.
The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 19 cents per share.
The drugmaker posted revenue of $79.5 million in the period, topping Street forecasts. Five analysts surveyed by Zacks expected $75 million.
For the year, the company reported that its loss widened to $247.1 million, or $1.33 per share. Revenue was reported as $270.8 million.
BioCryst shares have decreased 11% since the beginning of the year. The stock has decreased 46% in the last 12 months.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a BCRX">Zacks stock report on BCRX at https://www.zacks.com/ap/BCRX